Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer

L. F. de Geus-Oei; H. W. M. van Laarhoven; E. P. Visser; R. Hermsen; B. A. van Hoorn; Y. J. L. Kamm; P. F. M. Krabbe; F. H. M. Corstens; C. J. A. Punt; W. J. G. Oyen

doi:https://doi.org/10.1093/annonc/mdm470

Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer

L. F. de Geus-Oei, H. W. M. van Laarhoven, E. P. Visser, R. Hermsen, B. A. van Hoorn, Y. J. L. Kamm, P. F. M. Krabbe, F. H. M. Corstens, C. J. A. Punt, W. J. G. Oyen

Research output: Contribution to journal › Article › Academic › peer-review

100 Citations (Scopus)

Abstract

The aim of this prospective study was to evaluate the value of F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) for early assessment of chemotherapy response in patients with advanced colorectal cancer. Dynamic FDG-PET was carried out before and at 2 (n = 50) and 6 months (n = 19) after the start of treatment. Quantitative Patlak analysis [metabolic rate of glucose (MRGlu)] and a simplified method to measure glucose metabolism [standardized uptake value (SUV)] were evaluated. The predictive value of changes in glucose metabolism was assessed with Cox proportional regression analysis. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. There was an increase in the rates of death (P = 0.049 for DeltaMRGlu PET1-2; P = 0.017 for DeltaSUV PET1-2; P = 0.032 for DeltaMRGlu PET1-3; P = 0.048 for DeltaSUV PET1-3) and progression (P = 0.026 for DeltaMRGlu PET1-2; P = 0.035 for DeltaSUV PET1-2; P = 0.041 for DeltaMRGlu PET1-3; P = 0.081 for DeltaSUV PET1-3) associated with worse response as assessed by PET on Cox proportional regression analysis. The OS and PFS analysis showed a significant predictive value at broad ranges of DeltaMRGlu and DeltaSUV cut-off levels. The degree of chemotherapy-induced changes in tumor glucose metabolism is highly predictive for patient outcome. The use of FDG-PET for therapy monitoring seems clinically feasible since simplified methods (SUV) are sufficiently reliable

Original language	English
Pages (from-to)	348-352
Journal	Annals of Oncology
Volume	19
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdm470
Publication status	Published - 2008

Access to Document

https://doi.org/10.1093/annonc/mdm470

Cite this

@article{7b7bb92bc00e4adba577131a87422303,

title = "Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer",

abstract = "The aim of this prospective study was to evaluate the value of F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) for early assessment of chemotherapy response in patients with advanced colorectal cancer. Dynamic FDG-PET was carried out before and at 2 (n = 50) and 6 months (n = 19) after the start of treatment. Quantitative Patlak analysis [metabolic rate of glucose (MRGlu)] and a simplified method to measure glucose metabolism [standardized uptake value (SUV)] were evaluated. The predictive value of changes in glucose metabolism was assessed with Cox proportional regression analysis. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. There was an increase in the rates of death (P = 0.049 for DeltaMRGlu PET1-2; P = 0.017 for DeltaSUV PET1-2; P = 0.032 for DeltaMRGlu PET1-3; P = 0.048 for DeltaSUV PET1-3) and progression (P = 0.026 for DeltaMRGlu PET1-2; P = 0.035 for DeltaSUV PET1-2; P = 0.041 for DeltaMRGlu PET1-3; P = 0.081 for DeltaSUV PET1-3) associated with worse response as assessed by PET on Cox proportional regression analysis. The OS and PFS analysis showed a significant predictive value at broad ranges of DeltaMRGlu and DeltaSUV cut-off levels. The degree of chemotherapy-induced changes in tumor glucose metabolism is highly predictive for patient outcome. The use of FDG-PET for therapy monitoring seems clinically feasible since simplified methods (SUV) are sufficiently reliable",

author = "{de Geus-Oei}, {L. F.} and {van Laarhoven}, {H. W. M.} and Visser, {E. P.} and R. Hermsen and {van Hoorn}, {B. A.} and Kamm, {Y. J. L.} and Krabbe, {P. F. M.} and Corstens, {F. H. M.} and Punt, {C. J. A.} and Oyen, {W. J. G.}",

year = "2008",

doi = "https://doi.org/10.1093/annonc/mdm470",

language = "English",

volume = "19",

pages = "348--352",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer

AU - de Geus-Oei, L. F.

AU - van Laarhoven, H. W. M.

AU - Visser, E. P.

AU - Hermsen, R.

AU - van Hoorn, B. A.

AU - Kamm, Y. J. L.

AU - Krabbe, P. F. M.

AU - Corstens, F. H. M.

AU - Punt, C. J. A.

AU - Oyen, W. J. G.

PY - 2008

Y1 - 2008

N2 - The aim of this prospective study was to evaluate the value of F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) for early assessment of chemotherapy response in patients with advanced colorectal cancer. Dynamic FDG-PET was carried out before and at 2 (n = 50) and 6 months (n = 19) after the start of treatment. Quantitative Patlak analysis [metabolic rate of glucose (MRGlu)] and a simplified method to measure glucose metabolism [standardized uptake value (SUV)] were evaluated. The predictive value of changes in glucose metabolism was assessed with Cox proportional regression analysis. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. There was an increase in the rates of death (P = 0.049 for DeltaMRGlu PET1-2; P = 0.017 for DeltaSUV PET1-2; P = 0.032 for DeltaMRGlu PET1-3; P = 0.048 for DeltaSUV PET1-3) and progression (P = 0.026 for DeltaMRGlu PET1-2; P = 0.035 for DeltaSUV PET1-2; P = 0.041 for DeltaMRGlu PET1-3; P = 0.081 for DeltaSUV PET1-3) associated with worse response as assessed by PET on Cox proportional regression analysis. The OS and PFS analysis showed a significant predictive value at broad ranges of DeltaMRGlu and DeltaSUV cut-off levels. The degree of chemotherapy-induced changes in tumor glucose metabolism is highly predictive for patient outcome. The use of FDG-PET for therapy monitoring seems clinically feasible since simplified methods (SUV) are sufficiently reliable

AB - The aim of this prospective study was to evaluate the value of F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) for early assessment of chemotherapy response in patients with advanced colorectal cancer. Dynamic FDG-PET was carried out before and at 2 (n = 50) and 6 months (n = 19) after the start of treatment. Quantitative Patlak analysis [metabolic rate of glucose (MRGlu)] and a simplified method to measure glucose metabolism [standardized uptake value (SUV)] were evaluated. The predictive value of changes in glucose metabolism was assessed with Cox proportional regression analysis. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier estimates. There was an increase in the rates of death (P = 0.049 for DeltaMRGlu PET1-2; P = 0.017 for DeltaSUV PET1-2; P = 0.032 for DeltaMRGlu PET1-3; P = 0.048 for DeltaSUV PET1-3) and progression (P = 0.026 for DeltaMRGlu PET1-2; P = 0.035 for DeltaSUV PET1-2; P = 0.041 for DeltaMRGlu PET1-3; P = 0.081 for DeltaSUV PET1-3) associated with worse response as assessed by PET on Cox proportional regression analysis. The OS and PFS analysis showed a significant predictive value at broad ranges of DeltaMRGlu and DeltaSUV cut-off levels. The degree of chemotherapy-induced changes in tumor glucose metabolism is highly predictive for patient outcome. The use of FDG-PET for therapy monitoring seems clinically feasible since simplified methods (SUV) are sufficiently reliable

U2 - https://doi.org/10.1093/annonc/mdm470

DO - https://doi.org/10.1093/annonc/mdm470

M3 - Article

C2 - 17962202

SN - 0923-7534

VL - 19

SP - 348

EP - 352

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -